Stryker (NYSE:SYK) Sets New 12-Month Low – Should You Sell?

Stryker Corporation (NYSE:SYK)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $275.10 and last traded at $276.1560, with a volume of 6316453 shares changing hands. The stock had previously closed at $303.13.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Piper Sandler dropped their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. JPMorgan Chase & Co. decreased their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. BMO Capital Markets started coverage on Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target on the stock. Finally, Leerink Partners reduced their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Down 8.9%

The firm’s fifty day simple moving average is $327.52 and its 200-day simple moving average is $328.30. The company has a market cap of $105.93 billion, a PE ratio of 28.62, a P/E/G ratio of 1.90 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by corporate insiders.

Institutional Trading of Stryker

A number of hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System boosted its holdings in shares of Stryker by 30,523.4% during the second quarter. California State Teachers Retirement System now owns 163,395,348 shares of the medical technology company’s stock worth $51,443,391,000 after purchasing an additional 162,861,784 shares during the last quarter. Norges Bank acquired a new position in Stryker in the fourth quarter valued at $1,822,272,000. Bank of America Corp DE purchased a new position in Stryker during the second quarter worth about $1,404,284,000. Auto Owners Insurance Co boosted its stake in Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Stryker during the 2nd quarter valued at about $707,212,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.